Orca Bio

About

Orca Bio is helping to deliver the promise of cell therapy to patients without compromise. We’re redefining the traditional transplant process by developing next-generation cell therapies designed to provide significantly better outcomes with dramatically fewer risks. Our mission Orca Bio is redefining the traditional transplant process by developing next-generation cell therapies with the goal of providing significantly better survival rates with dramatically fewer risks. With our purified, high-precision investigational cell therapies we hope to not only replace patients' blood and immune systems with healthy ones, but also restore their lives. Our history We believe we can push past the field's current boundaries and redefine its future. Orca Bio began operations in 2016 based on research conducted by our founders in the laboratory of stem cell pioneer Dr. Irv Weissman at Stanford University. Our founders were inspired by the advancements made in the cell therapy field but believed the risks and limitations that have plagued this area for decades were unacceptable. Today we are focused on bringing this innovative research approach to patients. By combining proven scientific insights with a cell-sorting platform capable of single-cell accuracy, we are delivering purified, high-precision investigational cell therapies for patients. Our team spirit At Orca Bio, we are working to make the world a better place for patients and the people who love them. We look for people with big ideas We work as a team and have fun together We feel collaboration makes the magic We support bringing life-changing investigational therapies to patients From trips to local restaurants and group outings to regularly sharing exciting life updates, the team treats each other like a chosen family. Our dedication Every day, our employees enter our laboratories and manufacturing facilities committed to delivering our investigational cell therapies to patients because we believe in their life-saving potential. Since our founding, Orca Bio's leadership team has delivered on its mission, swiftly advancing our investigational therapies from their foundational science into the clinic We take pride in holding the unique position of being a late-stage company that has administered our investigational therapies to more than 400 patients, yet retaining the agility of a start-up Every Orca Bio employee supports the process of delivering life-changing investigational therapies to patients. We don't settle for the current way of doing things—we act with urgency because we know how many patients could potentially benefit from our investigational therapies.